恩度在腹膜后淋巴结转移癌放疗增敏作用的研究  

作　　者：李丹明[1] 王黎 孙新臣[1] 姜楠[1] 

机构地区：[1]南京医科大学第一附属医院,210029 [2]南京市建邺医院,210019

出　　处：《浙江临床医学》2017年第9期1611-1613,共3页Zhejiang Clinical Medical Journal

基　　金：江苏省第十二批“六大人才高峰”项目（WSW-024）

摘　　要：目的观察同步放化疗联合重组人血管内皮抑素（恩度）治疗腹膜后淋巴结转移癌（RLN）的疗效及安全性，探讨恩度在RLN治疗中的作用。方法回顾性分析2012年1月至2016年6月41例腹膜后转移淋巴癌患者的临床资料，依据病史分为恩度联合组（12例）和同步放化疗组（29例）。恩度联合组：替吉奥1000mg／m^2，口服，2次／d，d1-d14；恩度15mg，静脉滴注，d1-d14，3周为1个周期。放疗采用IMRT方法。同步放化疗组放化疗方案同上。分析所有患者临床资料及随访结果，分别评价疗效、生活质量、疼痛评分及不良反应，并用Kaplan-Meier法绘制生存曲线，Log-Rank检验进行两组比较。结果恩度联合组12例患者，有效率（RR）36．0％，疾病控制率（DCR）84．0％；中位无进展生存时间（PFS）11-2个月，中位总生存时间（OS）19．6个月；生活质量（QOL）改善稳定率75．0％，恩度联合治疗组治疗前后疼痛评分明显降低（P〈0．05）；放化疗组29例患者，RR13．1％，DCR63．1％；中位PFS12．3个月，中位0S15．6个月；QOL改善及稳定率62．1％。两组RR比较差异有统计学意义（P〈0．05）；两组DCR、QOL改善稳定率、中位PFS和中住OS比较差异均无统计学意义（P〉0．05），联合放化疗组治疗前后疼痛评分明显变化（P〉0．05）。两组患者不良反应差异无统计学意义（P〉0．05）。结论放化疗联合恩度治疗腹膜后转移癌优于放化疗组，提高患者生活质量，未增加副作用，恩度对腹膜后淋巴结转移癌的治疗有较好的放疗增敏作用。Objective To study the efficacy of concurrent chemoradiotherapy （ CRT ） combined with recombinant human endostatin （ rh- Endo ） in the treatment of retroperitoneal lymph node metastasis （ RLN ） . Methods From Jan 2012 to June 2012, 41 patients with RLN from digestive cancer were retrospectively analyzed, according to clinical data, patients were randomly assigned to rh-Endo＋ chemoradiotherapy （ CRT ） group （ 12 cases ） and CRT group （ 29 cases ） .For rh-Endo＋ CRT group： S1 ： 1000 mg/m^2, oral, bid, d1- d14. rh-Endo 15 mg, intravenous drip, d1- d14, 3 weeks for a cycle.The same scheme for CRT group. The clinical data and follow-up results for all patients were analyzed. Curative effect, quality of life （ QOL ） , pain relief score adverse reactions were respectively evaluated, drawing survival curve with Kaplan Meier （ Log-Rank test compared two groups ） . Results In rh-Endo＋ CRT group, the response rate （ RR ） was 36.0%, disease control rate （ DCR ） was 84.0%.Median progression-free survival （ PFS ） was 11.2 months and median overall survival （ OS ） was 19.6 months.The quality of life （ QOL ） improved and stable rate was 75.0%.Pain relief score decreased significantly between pre-treatment and post-treatment （ P〈0.05 ） . In CRT group, the response rate （ RR ） was 13.1%, disease control rate （ DCR ） was 63.1%.Median progression-free survival （ PFS ） was 12.3 months and median overall survival （ OS ） was 15.6 months.QOL improved and stable rate was 62.1%.There was statistical difference both in RR between the two groups （P〈0.05） .DCR, QOL, median PFS and median OS were similar between the two groups （ P〉0.05 ） . Pain relief score were similar between pre-treatment and post-treatment in CRT group （ P〉0.05 ） . There was no significant difference in adverse reactions between the two groups （ P〉0.05 ） . Conclusions Curative effect of rh-Endo combined with CRT is obviously superior to that of CRT in the treatment o

关 键 词：放疗增敏 腹膜后淋巴结转移癌 重组人血管内皮抑素 

分 类 号：R730.55[医药卫生—肿瘤]